The company, Family Farmstead Dairy, issued a raw cheddar recall over potential contamination with Shiga toxin-producing Escherichia coli (STEC) is happening across 7 states.
News|Articles|September 7, 2026
The Latest in Food: Updates on Outbreaks to Federal Policies Affecting Food Safety
Here's the latest on the cyclosporiasis and jalapeño-linked Salmonella case numbers, plus an update on the resolved avocado inspection halt. Also included is information on a bacterial infection linked to shellfish, and a look at efforts affecting cyclosporiasis research.
Advertisement
Advertisement
With ongoing food recalls and outbreaks as well as policies potentially changing, here is an update on the latest news.
Related to this article
CDC is continuing its investigation into 4 multistate Salmonella and E coli outbreaks, led by a 76-case alfalfa sprout cluster across 16 states and a recalled raw milk cheese.
Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.
The FDA approved bepirovirsen (Hibsago; GSK) with nucleos(t)ide analogue therapy for chronic hepatitis B, based on B-Well 1 and 2 functional cure rates of 19% vs 0% with placebo.
The latest CDC numbers show a 6.2% increase of measles cases from week-to-week. Last week there was a 5.4% increase in cases showing a continuing steady increase dictated by ongoing outbreaks across the US.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
The monoclonal antibody, Brelovitug, met the combined virologic and ALT response end point at week 24 in AZURE-1, with 56% response on 300 mg weekly and 45% on 900 mg every four weeks. The manufacturer projects a potential US launch in the fourth quarter of 2027.
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.
Advertisement
Advertisement